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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To estimate the accuracy of index tests for the detection of oral cancer and potentially malignant disorders of the lip and oral cavity in
patients presenting with clinically evident lesions.
To estimate the relative accuracy of the different tests.
We will use meta-regression to explore possible sources of heterogeneity. Covariates in these analyses will include:
• characteristics of the study sample: prevalence of the disease in the study, the type of specialist (e.g. frontline clinicians, specialists
and ’super-specialists’, i.e. those who see surveillance populations), setting (country, type of facility), proportion of human
papillomavirus positive adults, tobacco users/high alcohol consumption; and
• target conditions: the nature of target conditions included.
1Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
B A C K G R O U N D
Target condition being diagnosed
The target conditions of interest are oral squamous cell carcinoma
(OSCC), the most common form of oral cavity cancer (Scully
2000a), and potentiallymalignant disorders (PMD), of the lip and
oral cavity in patients presenting with clinically evident lesions. A
variety of terms have been used internationally to describe clini-
cal presentations that have the potential to become cancer. At a
meeting of international oral cancer and precancer experts held
in 2005, the concept of precancer, along with issues surrounding
classification and definition, aetiology, diagnosis and management
was extensively discussed. Through consensus, the term ’poten-
tially malignant disorders’ was selected to convey the fact that not
all precancerous lesions and conditions will transform to cancer,
but there is the potential for malignant transformation (van der
Waal 2009; Warnakulasuriya 2007).
The natural history of oral cancer is not fully understood, given
variations in disease processes and dysplastic changes in PMD
(Napier 2008; Scully 2009). Most oral carcinomas are preceded
by PMD, of which erythroplakia, non-homogeneous leukoplakia,
erosive lichen planus, oral submucous fibrosis and actinic kerato-
sis are perhaps the most important (Warnakulasuriya 2007). The
concept of a two-step process of cancer development of the oral
mucosa is established (i.e. precursor to established lesion). Oral
leukoplakia is the best-known precursor lesion and between less
than 1 and 18% of lesions develop into oral cancer. The origi-
nal 1978 World Health Organisation (WHO) definition of oral
leukoplakia has been revised to read “The term leukoplakia should
be used to recognize white plaques of questionable risk having ex-
cluded (other) known diseases or disorders that carry no increased
risk for cancer” (Warnakulasuriya 2007). The presence of epithe-
lial dysplasia can help predict malignant development but the di-
agnosis is essentially subjective, with not all lesions exhibiting dys-
plasia, some becoming malignant and some regressing. Carcinoma
can also develop from lesions in which epithelial dysplasia was
not previously diagnosed. Numerous attempts have been made
to relate biological characteristics to the malignant potential of
leukoplakias, but finding a definitive characteristic remains elu-
sive (Reibul 2003). Estimates of malignant transformation rates
(MTR) vary enormously, from site to site within the mouth, from
population to population and from study to study (Napier 2008).
The MTR of hospital-based surveys are consistently higher than
community-based studies because of sampling bias. Petti calcu-
lated a global MTR of oral leukoplakia of 1.36% per year (95%
confidence interval 0.69 to 2.03%) based on the prevalence of
leukoplakia (Petti 2003), but this far exceeds the numbers of actual
cases of malignancy. Virtually all studies emphasize the chronicity
of oral PMD, with an increasing tendency to malignant change
in the first 5 years. For example, the incidence of OSCC arising
from leukoplakia in Californians was greatest in the second year
of follow-up (11 out of 45; 24%) (Silverman 2004). The propor-
tion of PMD that will develop OSCC is uncertain but low; best
estimates suggest a rate of less than 2% per year (Napier 2008).
The early detection and excision of some PMD can prevent ma-
lignancy, or if malignancy is detected, there is some evidence
that appropriate treatment can reduce disease severity and im-
prove survival rates (Brocklehurst 2010; van der Waal 2009;
Warnakulasuriya 2007). Leukoplakias can be treated by a num-
ber of methods. According to Lodi et al’s systematic review (Lodi
2008), the effectiveness of surgical interventions, including laser
therapy and cryotherapy, has not been studied by means of a ran-
domised controlled trial (RCT) with a no treatment/placebo arm.
VitaminA and retinoids have been tested by five RCTs, two studies
investigated beta carotene or carotenoids, the other drugs tested
were bleomycin (one study), mixed tea (one study) and ketorolac
(one study). None of the treatments tested showed a benefit when
compared with the placebo. Lodi et al concluded that there was no
evidence of effective treatment in preventing the malignant trans-
formation of leukoplakia.Where resolution of a lesion is observed,
relapses and adverse effects are common.
Technologies to treat and manage oral cancer have progressed
substantially, as shown by Cochrane systematic reviews of RCTs
(Bessell 2011; Furness 2011; Glenny 2010). Patients presenting
with oral lesions persisting for more than 2 to 3 weeks are gen-
erally referred to an oral medicine specialist for further investi-
gation and to rule out malignancy (Scully 2000a; Scully 2000b;
Scully 2000c). Once progressed to frank malignancy, the tradi-
tional treatment is surgery and radiotherapy. More recently, sys-
temic chemotherapy has been included as part of the treatment
regimen before or during radiotherapy. Surgery for the treatment
of oral cancer is followed by exacting reconstructive surgery to
restore form and function. Debilitating side effects can occur as
a result of radiotherapy and chemotherapy, adversely affecting an
individual’s quality of life. The 5-year survival rate following di-
agnosis has remained at around 50% for the past 30 years in most
countries (Parkin 2001;Warnakulasuriya 2009). This is inmarked
contrast to the improved survival rates in many other cancers, such
as those of the breast and the colon (Cancer Research UK), but
may be explained at least in some part by the fact that oral cancer is
more often diagnosed at a late stage of the disease, when prognosis
is poorer and the risks of significant morbidity and mortality are
substantially higher (Rogers 2009; Rusthoven 2010).
Index test(s)
There is no standard practice for patients presenting with clini-
cally evident lesions that may carry a risk of cancer. Factors con-
tributing to this variation include geographical location and access
to clinical personnel. A conventional oral examination (COE), a
standard visual and tactile examination of the oral mucosa under
normal (incandescent) light by a frontline clinician such as a gen-
eral dentist is a common starting point. This can be considered as
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an opportunistic ’screen’. The assumption is that an examination
is performed to provide an opportunity for ’case-finding’ where
necessary. Upon discovering a lesion the clinician will make a sub-
jective judgement based upon the clinical presentation, their clin-
ical experience and training and the resources available to them
to decide on the next step. A fungating ulcerative mass that is ob-
viously an advanced malignancy needs little clinical acumen and
initiates an immediate referral. As we move earlier in the disease
spectrum, the clinical features become progressively less obvious
and the judgement as to whether a lesion is, or has, the potential
to become dysplastic or even malignant, and hence the next step
on the pathway becomes more difficult.
A number of index tests have been proposed for use by front-
line clinicians, specialists and ’super-specialists’ (i.e. those who see
surveillance populations) as adjuncts to a conventional oral cancer
examination for the purpose of improving diagnostic test accuracy
(Fedele 2009; Leston 2010; Lingen 2008; Patton 2008; Rethman
2010). These include:
• vital staining (toluidine blue, tolonium chloride);
• oral cytology (e.g. OralCDx brush biopsy);
• light-based detection (e.g. ViziLite and ViziLite Plus,
Microlux/DL, VELscope, Orascoptic DK, Identafi 3000) and
oral spectroscopy; and
• blood and saliva analysis.
Vital staining and oral cytology are long available diagnostic ad-
juncts to a conventional oral examination (Leston 2010; Lingen
2008). In this review, we will restrict vital staining index tests to
those applied to a lesion that has been visualized. A companion
Cochrane review ’Clinical assessment to screen for the detection
of oral cavity cancer and potentially malignant disorders in ap-
parently healthy adults’ will include vital staining index tests in
a rinse form, used as a screening adjunct in a general population
(Walsh 2012). Other tests such as light-based detection systems
have become commercially available only more recently. Blood
analysis and saliva analysis are more novel tests at an early stage of
evaluation.
It is worth noting there are regional differences in regulations on
the use of some of the above tests. For example, toluidine blue,
having been consistently rejected as a stand-alone technique, is
not cleared for use as a stand-alone screening technique in the
United States; it is included in the ViziLite Plus system. However,
the toluidine blue-only component is approved by the FDA as a
marking device.
There are a number of different uses for such diagnostic adjuncts
dependent on the pathway taken by the patient. Of the index tests
listed above, all have the potential to be used as diagnostic or case-
finding adjuncts to the COE by frontline clinicians (Additional
Table 1), specialists and ’super-specialists’, to aid in the more ac-
curate diagnosis of oral cancer and PMD. By including these tests,
the diagnostic process would be identification of clinically evident
lesions on the basis of clinical appearance and criteria and/or find-
ings from the index test(s), followed by biopsy where appropriate.
The tests could have a triage role in assisting the general dentist or
oral specialist to more accurately identify or assess persistent oral
lesions of uncertain significance. For instance, traumatic keratoses
are common, and referring each patient with a white patch to a
specialist to undergo a scalpel biopsy is excessive, and incurs in-
creased financial cost and patient worry. A non-invasive index test
or combination of tests adjunctive to the COE that provided a
frontline clinician with a high degree of accuracy would not only
reduce the number of patients with benign disease being referred,
but could avoid the need for invasive biopsy in patients testing
negative.
The index tests also have the potential to improve patient diagno-
sis at a secondary care level. Following referral to a specialist clinic,
the most important clinical step is to biopsy the area or areas rep-
resenting the worst disease. This is simple with a single homoge-
neous lesion but becomes more complicated when the lesion or
lesions become larger and more heterogeneous. Sample site selec-
tion may be facilitated by the diagnostic adjuncts, so performance
in a secondary care setting becomes important.
Finally, the tests could be useful in a surveillance setting such as
a cancer clinic where patients with a history of oral cancer or
PMDs are followed at specified times. This population is likely to
have had multiple biopsies, surgical procedures to treat cancer or
dysplastic changes, or other treatments such as radiation therapy.
Monitoring these patients for new disease (they often have field
changes) is challenging. The diagnostic adjuncts could be of value
in this setting.
Alternative test(s)
Medical imaging techniques such as computer tomography (CT),
other forms of tomography and magnetic resonance imaging
(MRI) have been used in addition to clinical evaluation. The di-
agnostic test accuracy of such techniques will not be considered
in this review.
Rationale
Oral cancer is a significant global health problem with increas-
ing incidence and mortality rates (Ferlay 2010; Warnakulasuriya
2009). Cancer of the lip or oral cavity is a relatively common can-
cer worldwide, with an estimated 263,000 new cases and 127,000
deaths in 2008, and an increasing incidence in recent years (Ferlay
2010). There is wide geographic variation in disease incidence
and mortality, with almost double the incidence in developing
countries as in developed countries, and a threefold increase in
mortality. Tobacco use, alcohol consumption, betel quid chewing
and low socioeconomic status are the most important risk factors
of oral cancer (Conway 2008; Faggiano 1997; La Vecchia 1997;
Macfarlane 1995). Men have a higher incidence of oral cancer
than women, but this disparity can be explained by men having a
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higher exposure to the above risk factors (Freedman 2007). The
gender difference has narrowed in recent decades from a ratio of 5
males to 1 female diagnosed with oral cancers in the 1960s to less
than 2 to 1 in 2008 (Ferlay 2010). Although traditionally the risk
of oral cancer increases with age, the incidence among younger
adults has increased in the European Union and the United States
(Warnakulasuriya 2009). Technologies to treat and manage oral
cancer have progressed substantially, as shown by Cochrane sys-
tematic reviews of RCTs (Furness 2011; Glenny 2010). Never-
theless, the 5-year survival following diagnosis has remained at
around 50% for the past 30 years in most countries (Parkin 2001;
Warnakulasuriya 2009).
The five year survival rate depends on the site of the cancer, rang-
ing from more than 90% for the lip to 40% for the oropharynx
(Cancer Research UK). Oral cancer is often diagnosed at a late
stage, when the prognosis is poor and the risks of significant mor-
bidity and mortality are substantially higher (Rusthoven 2010).
Oral cancer mortality can be reduced using three approaches: (i)
primary prevention, (ii) secondary prevention, screening and early
detection, and (iii) improved treatment (Scully 2000a).
Currently, no national population-based screening programmes
for oral cancer have been implemented in developed countries, al-
though opportunistic screening has been advocated (Brocklehurst
2010). Consequently, individuals will often present for examina-
tion at a later stage of the disease, when the risks of significant
morbidity and mortality are substantially higher. A province-wide
programme is being evaluated in British Columbia, Canada but
the evaluation is ongoing and no final results have been reported
to date (Rosin 2006). Brocklehurst et al’s Cochrane systematic re-
view identified one RCT in India. They concluded that the ev-
idence is insufficient to recommend population-based screening
and suggested that opportunistic screening of high risk groups
may potentially improve outcomes (Brocklehurst 2010). Accurate
case detection and early treatment of oral cancers can substantially
improve an individual’s morbidity, mortality and quality of life
(Scully 2000a; Stell 1982).
There is some uncertainty on the diagnostic accuracy of the in-
dex tests listed above. Review studies have identified a number of
these tests for oral cancer in individuals with an identified lesion
(Leston 2010; Lingen 2008; Patton 2008). The focus of these re-
views, however, has been on a description of the sensitivities and
specificities of diagnostic tests rather than a comprehensive qual-
ity assessment of studies and meta-analysis of all available data.
The index tests have the potential to improve the accuracy of oral
cancer diagnosis and to detect the disease at an earlier stage. This
could result in improved diagnostic decisions, leading to appro-
priate treatment pathways and ultimately improved patient out-
comes.
In this review we aim to identify diagnostic tests for oral cancer
and PMD and to evaluate the diagnostic accuracy of these tests
(Additional Table 1) when used as adjuncts to a COE by frontline
clinicians, specialists and ’super-specialists’. The proposed index
tests cannot confirm whether a PMD is cancerous before deciding
on referral to secondary care; biopsy with histopathology is cur-
rently the only confirmatory method of oral cancer diagnosis.
The Cochrane Oral Health Group has undertaken a number of
intervention reviews in the field of treatment of oral and oropha-
ryngeal cancers, and in screening programmes for the early de-
tection and prevention of oral cancer (Bessell 2011; Brocklehurst
2010; Furness 2011; Glenny 2010). This diagnostic test accuracy
review will complement the intervention reviews.
O B J E C T I V E S
To estimate the accuracy of index tests for the detection of oral
cancer andpotentiallymalignant disorders of the lip andoral cavity
in patients presenting with clinically evident lesions.
Secondary objectives
To estimate the relative accuracy of the different tests.
Investigation of sources of heterogeneity
We will use meta-regression to explore possible sources of hetero-
geneity. Covariates in these analyses will include:
• characteristics of the study sample: prevalence of the disease
in the study, the type of specialist (e.g. frontline clinicians,
specialists and ’super-specialists’, i.e. those who see surveillance
populations), setting (country, type of facility), proportion of
human papillomavirus positive adults, tobacco users/high
alcohol consumption; and
• target conditions: the nature of target conditions included.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies of clinical cohorts of patients presenting with clinically
evident lesions which report the diagnostic accuracies of any indi-
vidual index test listed in ’Additional Table 1’, or a combination of
these for oral cancer and potentially malignant disorders (PMD)
with respect to the reference standard. These will include cross-
sectional diagnostic test accuracy studies (or consecutive series)
and randomised controlled trials. We will exclude studies reported
in abstract form alone, case-control studies, uncontrolled reports
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and randomised controlled trials of the effectiveness of screening
programmes (intervention studies). Where randomised or paired
comparative designs are available these will be included in the re-
view. Studies analysing only lesions, rather than patients, will be
excluded. We will contact authors of studies that report only re-
sults at the lesion level for data at the patient level; if authors are
able to provide such data, their studies will be included.
Participants
Adult patients (aged 16 years or over) presenting with clinically
evident oral lesions.
Index tests
Index tests used alone or in combination that can be used as an
adjunct to the conventional oral examination (Additional Table
1). The COE based on clinical appearance and criteria is the initial
point of diagnosis, which all adults will receive. The remaining
index test(s) will be used as an adjunct following the conventional
oral examination (COE) irrespective of whether oral cancer or
PMD is suspected by the COE alone (i.e. a positive test result is a
positive result from either the COE or the index test or both).
Target conditions
Following the consensus views of the expert working group of
the WHO collaborating centre for oral cancer and precancer (
Warnakulasuriya 2007), the target conditions of the lip or oral
cavity of interest are noted as:
Carcinoma
• Squamous cell carcinoma
Potentially malignant disorders (PMDs)
• Leukoplakia
• Erythroplakia
• Lichen planus
• Lupus erythematosus
• Submucous fibrosis
• Actinic keratosis
• Hereditary disorders such as dyskeratosis congenita or
epidermolysis bullosa
Reference standards
Scalpel, punch or fine needle aspiration biopsy with histological
confirmation of lesion.Wewill exclude studies that did not specify
any reference standard.
Search methods for identification of studies
Electronic searches
The following databases will be searched using a highly sensitive
search strategy:
• Cochrane Oral Health Group’s Trials Register (to present)
• Cochrane Register of Diagnostic Test Accuracy Studies (to
present)
• MEDLINE (1948 to present)
• EMBASE (1980 to present)
• MEDION (2003 to present).
The MEDLINE search strategy outlined in Appendix 1 will be
modified for the listed databases. The search will not be limited by
language or publication status. Non-English articles will be trans-
lated, unless a translator cannot be found through The Cochrane
Collaboration.
The search strategy above has been constructed in accordance with
this protocol and that of a companion Cochrane diagnostic test
accuracy review ’Clinical assessment to screen for the detection of
oral cavity cancer and potentially malignant disorders in appar-
ently healthy adults’ by the same review team (Walsh 2012).
Searching other resources
Wewill also search relevant conference proceedings.We will locate
further studies through citation searches and reference lists of key
articles, and by contacting authors of identified articles to request
information of any unpublished or ongoing studies.
Data collection and analysis
Selection of studies
Titles and abstracts of all articles identified from the electronic
searches will be independently assessed by two review authors.
For articles that appear to meet the inclusion criteria, or where
a clear decision cannot be made from scanning the title and ab-
stract alone, full reports will be obtained. Full reports will also
be obtained from searching other resources. Two review authors
will independently assess each report. Where disagreements occur,
the review authors will attempt to resolve these by discussion. If
needed, a third review author will be asked to help resolve any
discrepancies in consultation with the other two review authors.
Data extraction and management
Two review authors will independently extract data using a piloted
data collection form. Discrepancies will be resolved through dis-
cussion. If an agreement cannot be reached, a third review author
will be consulted. Study authors will be contacted to obtain rele-
vant missing data if this is not available in the printed report.
The following data will be recorded from each study.
• Sample characteristics (age, sex, socioeconomic status, risk
factors where stated (e.g. human papillomavirus status positive/
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negative, prevalence of tobacco use and alcohol consumption),
number of patients/lesions, lesion site)
• Setting (country, disease prevalence, type of facility)
• The type of index test(s) used (category, name, positivity
threshold)
• Study information (design, reference standard, case
definition, training and calibration of personnel)
• Study results (true positive, true negative, false positive,
false negative, any equivocal results, withdrawal).
Data will be extracted by subgroups (tobacco and alcohol con-
sumption) where available.
Assessment of methodological quality
Two review authors will each independently assess the quality of all
studies selected for inclusion in the review. Where disagreements
continue after discussion between the two review authors, a third
review author will be asked to help resolve the discrepancies. The
revised QUADAS tool, QUADAS-2 (Whiting 2011), will be used
to assess the quality of the primary diagnostic studies over four key
domains: patient selection, index test, reference standard and flow
and timing of participants through the study. In the first phase
of the tool, the review question will be stated in terms of patient
sample, index test, reference standard and target condition. This
information is detailed in the ’Criteria for considering studies for
this review’ section of this protocol. In phase two, the QUADAS-
2 tool will be tailored to use with this review (Additional Table
2). Review specific guidance will be used to facilitate documen-
tation of the pertinent descriptive information contained in the
primary studies. Customised instructions to aid judgement of the
signalling questions will be given (following Patton 2008). Two
core signalling questions were removed: ’Was a case-control design
avoided?’ (this study design was excluded from the review); and
’Did all patients receive a reference standard?’ (this was a crite-
rion for inclusion). Three additional signalling items relating to
commercial funding, training and calibration and multiple index
tests have been added to the core signalling questions. In phase
three, a flow diagram will be drawn. In the final phase, an overall
judgement of risk of bias and applicability is to be undertaken. A
risk of bias judgement (’high’, ’low’ or ’unclear’) will be reached
for each domain. If the answers to all signalling questions within
a domain are judged as ’yes’ indicating low risk of bias, then the
domain will be judged to be at low risk of bias. If any signalling
question within a domain is judged as ’no’ indicating high risk
of bias then this indicates that potential bias exists. This will be
followed by a judgement for concerns regarding applicability for
the patient selection, index test and reference standard domains.
We will pilot the use of the QUADAS -2 tool independently on
five study reports. Where disagreements occur between the two
review authors the review specific descriptions will be clarified
until consistency is obtained.
Results of the quality assessment for all included studies will be
summarised in a narrative report. A summary tabular presentation
of the results for each domain will be also provided separately
for risk of bias and concerns regarding applicability, along with a
graphical display summarising this information.
Statistical analysis and data synthesis
The unit of analysis is the patient. Data for the true positive, true
negative, false positive and false negative values for each study will
be tabulated. For each index test, estimates of diagnostic accuracy
as sensitivity and specificity along with their 95% confidence in-
tervals will be displayed as coupled forest plots, and plotted in
receiver operating characteristic (ROC) space. We will take the
number of diseased and non-diseased individuals as the sample
size, not the total number of lesions.
Meta-analysis will be used to combine the results of studies for each
index test. Random-effects models will be used. If the number of
studies is small and themodel parameters unestimable thenwewill
follow the suggested approaches inChapter 10 theCochrane Hand-
book for Systematic Reviews of Diagnostic Test Accuracy (Macaskill
2010), e.g. moving from a random-effects model to a fixed-effect
model, or separately modelling sensitivity and specificity. The sta-
tistical software SAS 9.2 will be used throughout (SAS Institute
Inc, Cary, USA).
For the vital staining, brush cytology and light-based detection
methods, consistency in thresholds is anticipated as the test is
deemed positive if any sign of malignancy or potential malignancy
is detected. It is acknowledged that variation in test calibration
and individual performance may contribute to heterogeneity. The
analysis will estimate the expected values of sensitivity and speci-
ficity (bivariate approach Reitsma 2005). For the analysis of blood
and salivary index tests, primary studies may evaluate these tests
at many different thresholds within the same study, or between
studies. The expected summary ROC (SROC) curve for the tests
across different thresholds will be estimated (hierarchical SROC
Macaskill 2010; Rutter 2001). Hierarchical SROC curves will be
fitted using the Proc NLMixed procedure in SAS.
The proposed analysis is subject to change based on information
reported in the primary studies. For example, if there is little vari-
ation in the positive thresholds of the blood and salivary index
tests, it will not be appropriate to attempt to fit an SROC curve
(Macaskill 2010).
The analysis plan can be specified as follows:
Primary analyses: The primary analyses will compare each index
test with the reference standard. This will either estimate the av-
erage sensitivity and specificity of a test or describe the variation
in sensitivity and specificity at different thresholds by estimating
a hierarchical SROC curve depending on the nature of the index
tests. Parameter estimates will include sensitivity, specificity and
their correlation or hierarchical SROC curve.
Secondary analysis: The comparative accuracy of the index tests
with the reference standard will be the focus of the secondary anal-
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yses. A preliminary analysis will graphically display the sensitivities
and specificities of the index tests. This will be followed by a series
of indirect pairwise analyses and structured as follows.
• Vital staining versus brush cytology
• Light detection versus brush cytology
• Blood/salivary analysis versus brush cytology
• Vital staining versus light detection
• Vital stain versus blood/salivary analysis
• Light detection versus blood/salivary analysis.
All studies will be included in each pairwise comparison. Where
studies of direct comparisons exist (i.e. paired data from all patients
or randomising individuals to different tests) the results of these
studies will be analysed and reported separately.
Themethodology used is akin to the investigation of heterogeneity
(as below) i.e. adding a covariate for test type into the bivariate or
hierarchical SROC analysis.
Investigations of heterogeneity
Meta-regression analyses will be carried out to explore possible
sources of heterogeneity, ways inwhich the observed diagnostic test
accuracy varies according to particular characteristics. Covariates
in these analyses will include:
• characteristics of the study sample: prevalence of the disease
in the study, the type of specialist (e.g. frontline clinicians,
specialists and ’super-specialists’, i.e. those who see surveillance
populations), setting (country, type of facility), proportion of
human papillomavirus positive adults, tobacco users/high
alcohol consumption; and
• target conditions: the nature of target conditions included.
The log likelihood of models including the covariate will be com-
pared to those models without the covariate. Formal model com-
parisons will be undertaken using the likelihood ratio statistic to
statistically compare the effects of adding or removing covariates.
If statistical evidence of heterogeneity is found, further investiga-
tions will be undertaken.
Sensitivity analyses
Sensitivity analyses will be conducted. This will entail restrict-
ing the analysis to studies where the reference standard is scalpel
biopsy followed by histopathology. Binary categorisations which
relate to decision making in clinical practice will be utilised for
multiple disease categories (i.e. including equivocal results as pos-
itive screen, negative screen or omitting from reported results). If
no consensus is found, consideration of alternative categorisations
will be explored through sensitivity analysis.
Assessment of reporting bias
Tests for reporting bias will not be conducted because current tests
are misleading when applied to systematic reviews of diagnostic
test accuracy (Leeflang 2008; Tang 2000).
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A D D I T I O N A L T A B L E S
Table 1. Index tests for oral cancer and PMDs
Test Characteristics Classification of response Other information
Conventional oral examination
(COE)
A standard visual and tactile
examination of the oral mu-
cosa under normal (incandes-
cent) light
The presence of an oralmucosal
abnormality with a suspicion of
malignancy or potential malig-
nancy is classified as a positive
test result; the presence of oral
mucosal abnormality without a
suspicion of malignancy or po-
tential malignancy is classified
as a negative test result
Traditionally used as a oral can-
cer screen rather than diagnosis,
but its utility is debated (Lingen
2008).
Advantages: quick and easy
once trained, minimally inva-
sive.
Disadvantages: oral mucosal
abnormalities are not necessar-
ily clinically or biologically ma-
lignant; only as small percent-
age of leukoplakias are pro-
gressive or become malignant,
COE cannot distinguish be-
tween those that are or are
not; some precancerous lesions
may exist within oral mucosa
that appears clinically normal
by COE alone (Lingen 2008).
Vital staining (e.g. toluidine
blue, tolonium chloride)
Vital staining refers to the use
of dyes such as toluidine blue or
tolonium chloride to stain oral
mucosa tissues for PMD orma-
lignancy (Leston 2010; Lingen
2008; Patton 2008). The pro-
cedure is as follows.
• Pre-rinse with acetic acid
• Rinse with water
• Apply toluidine blue
• Post rinse with acetic acid
• Rinse with water
• Observe mucosa to check
for staining.
The result of the test is classified
as positive if tissue is stained and
negative if no tissue is stained,
or equivocal if no definitive re-
sult can be obtained
Advantages: ability to define
areas that could bemalignant or
abnormal but cannot be seen;
assess the extent of the PMDfor
excision
Disadvantages: benign inflam-
matory lesions are subject to
stain; possibility of failure of
some cancerous lesions to stain;
possibility of failure of some
dysplastic lesions (particularly
those with a lower grade or
with a thick keratotic surface)
to stain; variation in test perfor-
mance depending on how thor-
ough the test procedures are fol-
lowed; contraindicated in those
who are known to be allergic to
iodine
Brush cytology (e.g. OralCDx
brush biopsy)
Brush cytology refers to the mi-
croscopic assessment and in-
terpretation of cell samples
from PMD that are flaked off
from the oral mucosa by the
brushing, smearing, scraping or
Following analysis, cytopathol-
ogists classify test results as pos-
itive, atypical or negative
Advantages: include the abil-
ity to collect information from,
and detect large or multiple le-
sions and to access “the base-
mentmembrane collecting cells
from all three epithelial layers
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Table 1. Index tests for oral cancer and PMDs (Continued)
lavage to collect cell samples,
which are then sealed on glass
slides. They are then analysed
using an imaging system that as-
sesses the sampled cells (Leston
2010; Lingen 2008; Patton
2008).
of the oral mucosa. The liq-
uid-based cytology reduces the
problems relating to sampling
and fixation and presents a bet-
ter cytological morphology” (
Divani 2009).
Disadvantages: smaller or less
obvious lesions may be over-
looked; difficulties in detecting
lesions when there is necrosis or
coagulated blood; inadequate
training of operators (Divani
2009); cells are potentially seen
out of context.
Light-based detection (chemi-
luminescence e.g. ViziLite,
ViziLite plus, Microlux DL; tis-
sue fluorescence imaging e.g.
VELscope, Identafi 3000; tissue
fluorescence spectroscopy)
Light-based systems to identify
malignant and potentially ma-
lignant lesions and to highlight
their presence through tissue re-
flectance (Leston 2010; Lingen
2008; Patton 2008) e.g. using
Microlux DL, the procedure is
as follows (Lingen 2008).
• Pre-rinse with acetic acid
• Use blue-light light
source to visually assess the
oral cavity.
ViziLlite Plus also provides
a tolonium chloride solution
(toluidine blue) to aid in the
marking of the lesion for biopsy
once the light source is removed
The result of the test is classed
as negative if the appearance of
the epithelium is lightly bluish
white and positive if the appear-
ance of the epithelium is dis-
tinctly white (acetowhite)
Advantages: simple to use;
non-invasive; do not require
consumable reagents; provide
real time results; can be per-
formed by a wide range of op-
erators after a short training pe-
riod
Disadvantages: the necessity of
a dark environment; high ini-
tial set up (for VELscope) or
recurrent costs (for ViziLite in
low income countries); lack of
permanent record unless pho-
tographed; inability to objec-
tively measure visualisation re-
sults
Blood and saliva analysis These novel technologies are
at an early stage of develop-
ment and evaluation. Analy-
sis of blood or saliva samples
which tests for the presence of
biomarkers of PMD and oral
cancer (Brinkmann 2011; Lee
2009; Li 2006).
Cutoff probabilities vary widely
and are dependent on the indi-
vidual biomarker or combina-
tion of biomarkers examined
Advantages: non-invasive
(saliva tests) or minimally inva-
sive (blood tests)
Disadvantages: there is a ten-
dency for the estimated diag-
nostic accuracy of new health
technologies to decline over
time as evidence from inde-
pendent evaluations accumu-
late (Wyatt 1995). This bias,
which can be substantial, has
been demonstrated in other do-
mains, e.g. acute abdominal
pain (Liu 2006) and clinical
decision support systems (Garg
2005). Promising biomarker
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Table 1. Index tests for oral cancer and PMDs (Continued)
tests in several clinical areas
were eventually been shown
to be disappointing (Buchen
2011). It remains to be seen
whether this is the case with oral
cancer and PMDs
PMD = potentially malignant disorders
Table 2. Indicators for the assessment of quality (QUADAS-2)
Domain Patient selection Index test Reference standard Flow and timing
Description Describe methods of pa-
tient selection.
Describe
included patients (char-
acteristics, prior testing,
presentation and severity
of the target condition
(class), intended use of
index test and setting).
Describe the index test
(s) and how it was con-
ducted and interpreted.
Describe the sequence of
tests, any training or cali-
bration of clinicians (lev-
els of agreement should
be reported; where this is
measured by the kappa
statistic, acceptable val-
ues
range from 0.61 (mod-
erate agreement) to 1.
00 (almost perfect agree-
ment) (Landis 1977)),
any procedures taken to
ensure blinding of exam-
iners, post-hoc or a priori
threshold specification,
any conflict of interest
or commercial funding.
Methods of site selection
should be clearly docu-
mented
Describe the reference
standard and how it was
conducted and inter-
preted. Ideally, the biop-
sied tissue should be ex-
amined by more than
one pathologist. If there
is a lack of agreement
any methods for reach-
ing consensus should be
clearly documented. Any
measures taken to en-
sure pathologists were
blinded to the results of
the index tests should be
documented, along with
the sequence of reference
and index tests.Methods
of site selection should
be clearly documented
Describe the character-
istics and proportion of
patients who did not
receive the index test
(s) and/or reference stan-
dard, who received a
reference standard other
than the scalpel biopsy,
or who were excluded
from the 2 x 2 table
(refer to flow diagram)
. Describe the time in-
terval and any interven-
tions between index test
(s) and reference stan-
dard. The length of time
between the index test
and reference standard
should be short in the
majority of cases. If the
period elapsed between
index test and reference
standard is greater than
2 weeks then this will be
considered an unaccept-
able delay
Signalling questions
(Yes/No/Unclear)
Was a consecutive or ran-
dom sample of patients
enrolled?
Classify as ’Yes’ if consec-
utive patients or a ran-
dom sample of individu-
als were recruited
Classify as ’No’ if non-
Was calibration of exam-
iners undertaken and re-
sults reported?
Classify as ’Yes’ if the ex-
aminers participated in
dedicated training and
calibration was reported
to an acceptable standard
Is the reference standard
likely to correctly classify
the target condition?
Clas-
sify as ’Yes’ if the biopsy
was independently con-
firmed by at least two
qualified pathologists
Was there an appropri-
ate time interval between
the index test(s) and ref-
erence standard?
Classify as ’Yes’ if the
delay between the in-
dex test(s) and reference
standard is considered
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Table 2. Indicators for the assessment of quality (QUADAS-2) (Continued)
consecutive patients or
a non-random sample
of individuals were re-
cruited
Classify as ’Unclear’ if
patient selection was not
clearly described.
Classify as ’No’ if the ex-
aminers did not partici-
pate in dedicated train-
ing or was not assessed,
or training was under-
taken but calibrationwas
not to an acceptable
standard
Classify as
’Unclear’ if the informa-
tion on training and cal-
ibration was not stated
Classify as ’No’ if the
biopsy was not inde-
pendently confirmed by
at least two qualified
pathologists, or therewas
lack of agreement be-
tween pathologists
Classify
as ’Unclear’ if the study
does not state who con-
firmed the biopsy.
acceptable for themajor-
ity of participants
Classify as ’No’ if the
delay between the in-
dex test(s) and reference
standard is considered
unacceptable for the ma-
jority of participants
Classify as ’Unclear’ if
the delay between the in-
dex test(s) and reference
standard is not explicitly
stated
Did the study avoid in-
appropriate exclusions?
Classify as ’Yes’ if pa-
tients with either class I
or class II lesions were re-
cruited
Classify as ’No’ if only
patients with class I le-
sions were recruited.
Classify as ’Unclear’ if
class of lesions was not
clearly described.
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
Classify as ’Yes’ if in-
terpreters of index test
results clearly do not
know results of biopsy/
histopathology
Classify as ’No’ if inter-
preters of index test re-
sults clearly know results
of biopsy/
histopathology
Classify
as ’Unclear’ if study did
not provide any infor-
mation on whether in-
terpreters of index tests
were blinded to biopsy/
histopathology
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Classify as ’Yes’ if pathol-
ogists clearly do not
know the index test re-
sults when interpreting
biopsied tissues
Classify as ’No’ if pathol-
ogists know the results of
index test results when
interpreting biopsied tis-
sues
Classify as ’Unclear’ if
the study did not pro-
vide any information on
whether the pathologists
were blinded to the index
test results
Did all patients receive
the same reference stan-
dard?
Classify as ’Yes’ if the
same reference standard
was used in all partici-
pants
Classify as ’No’ if the
same reference standard
was not used in all par-
ticipants
Classify as ’Unclear’ if it
is unclear whether differ-
ent reference standards
were used
Where multiple index
tests were used, were the
results of the second in-
dex test interpretedwith-
out knowledge of the re-
sults of the first index
test?
Classify as ’Yes’ if index
test results were inter-
preted without knowl-
edge.
Classify as ’No’ if the
Were all patients in-
cluded in the analysis?
Classify as ’Yes’ if all pa-
tients were included in
the analysis.
Classify as ’No’ is only
some patients were in-
cluded in the analysis.
Classify as ’Unclear’ if it
is unclear whether all pa-
tients were included in
the analysis.
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Table 2. Indicators for the assessment of quality (QUADAS-2) (Continued)
index test results were
interpreted with knowl-
edge.
Classify as ’Unclear’ if it
is unclear whether the re-
sults of the second in-
dex test were interpreted
without knowledge of
the results of the first in-
dex test?
If a threshold was used,
was it prespecified?
Classify as ’Yes’ if the
threshold was prespeci-
fied.
Classify as ’No’ if the
threshold was not pre-
specified.
Classify as ’Unclear’ if
it is unclear whether the
threshold was prespeci-
fied.
Were any conflicts of in-
terest stated?
Classify as ’Yes’ if the
study declared no con-
flict of interest.
Classify as ’No’ if the
study if the study de-
clared a conflict of inter-
est.
Classify as ’Un-
clear’ there was no infor-
mation on conflict of in-
terest.
Risk of bias: High/Low/
Unclear
Could the selection of
patients have introduced
bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?
Could the patient flow
have introduced bias?
Concerns regard-
ing applicability: High/
Low/Unclear
Are there concerns that
the included patients do
not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp Mouth/
2. Cheek/
3. or/1-2
4. exp Carcinoma, squamous cell/di
5. exp Precancerous conditions/di
6. (tumor$ or tumour$ or cancer$ or carcinoma$ or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or
ulcer$).tw,ot.
7. (pre-cancer$ or precancer$ or premalignan$ or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic
adj2 keratosis) or candidiasis or erythroplakia or erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkeratos$).tw,ot.
8. or/4-7
9. 3 and 8
10. exp Mouth neoplasms/di
11. Lichen Planus, Oral/di
12. Oral submucous fibrosis/di
13. Oral candidiasis/di
14. ((oral$ or mouth$ or bucca$ or “oral cavit$” or (oral adj mucosa$) or (mouth adj mucosa$) or lip or lips or tongue$ or gingiv$
or palat$ or cheek$ or “intra oral$” or intraoral$ or gum or gums or labial$) adj3 (tumor$ or tumour$ or cancer$ or carcinoma$
or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or ulcer$ or pre-cancer$ or precancer$ or premalignan$
or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic adj2 keratosis) or candidiasis or erythroplakia or
erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkerato$)).tw,ot.
15. or/10-14
16. 9 or 15
17. Cytodiagnosis/
18. Cytological techniques/
19. Cytophotometry/
20. (brush adj3 biops$).tw,ot.
21. (“oral cdx” or oralcdx).tw,ot.
22. (“modified liquid based cytology” or (exfoliat$ adj3 cytolog$)).tw,ot.
23. (brush$ and (cytodiagnosis or cytopathology)).tw,ot.
24. Tolonium chloride/du
25. Coloring agents/du
26. (“tolonium chloride” or “tolu?dine blue” or “tolu?dine b” or tblue or t-blue).tw,ot.
27. (tolu?dine adj6 (dye$ or rins$ or stain$ or wash$)).tw,ot.
28. exp Luminescence/du
29. Fluorescence/
30. Spectrometry, fluorescence/
31. exp Luminescent Agents/du
32. Light/du
33. Tomography, Optical Coherence/
34. (visual$ adj5 (“light emitting diode” or “blue spectrum” or LED or luminous$)).tw,ot.
35. (visuali?ation adj3 adjunct$).tw,ot.
36. (vizilite or microlux$ or orascoptic or velscope).tw,ot.
37. lumenoscop$.tw,ot.
38. ((tumor$ or tumour$ or cancer$ or carcinoma$ or neoplas$ or carcinogen$ or malignan$ or metata$ or lesion$ or ulcer$) adj5
(fluorescen$ or autofluorescen$ or luminescen$ or chemiluminescen$)).tw,ot.
39. (tissue adj3 reflect$).tw,ot.
40. Spectrophotometry/
41. Acetic acid/du
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42. (acetic acid adj3 (wash$ or rins$)).tw,ot.
43. acetowhite.tw,ot.
44. Saliva/an, ch
45. Tumor Markers, Biological/an
46. ((“tumo?r marker$” or “neoplas$ marker$”) adj3 (blood or saliva)).tw,ot.
47. ((analy$ or screen$ or test$ or examin$) adj3 (blood or saliva)).tw,ot.
48. Diagnosis, Oral/
49. Mass screening/
50. Physical examination/
51. ((oral$ or mouth$) adj5 (exam$ or histolog$ or check$ or inspect$)).tw,ot.
52. (visual$ adj3 (exam$ or inspect$ or screen$)).tw,ot.
53. or/17-52
54. 16 and 53
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